AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of IQ motif and SEC7 domain-containing protein 2 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into IQ motif and SEC7 domain-containing protein 2 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of IQ motif and SEC7 domain-containing protein 2, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on IQ motif and SEC7 domain-containing protein 2. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of IQ motif and SEC7 domain-containing protein 2. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for IQ motif and SEC7 domain-containing protein 2 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
IQ motif and SEC7 domain-containing protein 2
partner:
Reaxense
upacc:
Q5JU85
UPID:
IQEC2_HUMAN
Alternative names:
-
Alternative UPACC:
Q5JU85; A0A1W2PQN3; B3KT97; C7SDG1; O60275; Q5JUX1
Background:
IQ motif and SEC7 domain-containing protein 2, encoded by the gene with accession number Q5JU85, plays a crucial role as a guanine nucleotide exchange factor for ARF GTP-binding proteins. This protein is pivotal in cellular processes, facilitating the activation of ARF proteins by promoting the exchange of GDP for GTP.
Therapeutic significance:
The protein is linked to Intellectual developmental disorder, X-linked 1, a condition marked by significantly below average intellectual functioning and impairments in adaptive behavior. This association highlights the protein's potential as a target for therapeutic intervention in treating or managing this disorder.
